SK Inc.; SK pharmteco

Yposkesi, SK pharmteco’s clinical and commercial viral vector manufacturing subsidiary for Cell and Gene Therapy (C>), completes its second bioproduction facility and doubles its manufacturing footprint to 10,000m2, one of the largest in Europe Operation of the second facility to kick start in 2024 SEOUL, South Korea, June 22, 2023 /PRNewswire/ — SK pharmteco, SK … Read more

Yposkesi, SK pharmteco’s clinical and commercial viral vector manufacturing subsidiary for Cell and Gene Therapy (C>), completes its second bioproduction facility and doubles its manufacturing footprint to 10,000m2, one of the largest in Europe Operation of the second facility to kick start in 2024 SEOUL, South Korea, June 23, 2023 /PRNewswire/ — SK pharmteco, SK … Read more